ADVANCED SOLID TUMOURS

This early-stage study is testing a new drug called LM-168, both alone and combined with an existing immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The first phase aims to find safe dose levels, while the sec…

This is the first study in humans testing a new drug called SIM0610 for people with advanced solid tumors that have spread or can't be removed by surgery. The trial will enroll 260 adults with cancers like lung, colorectal, liver, and head/neck cancer who have tried standard trea…

This early-stage study is testing a new drug called PYX-201 in combination with an existing immunotherapy (pembrolizumab) for people with advanced solid tumors. The main goals are to find the safest and most effective dose and to see how well the body handles the two drugs togeth…

This is a first-in-human study to test the safety of a new drug called RC220 when given with the common chemotherapy drug doxorubicin. It will involve about 53 adults with advanced solid tumors who may benefit from anthracycline treatment. The main goals are to find the safest do…

This is an early-stage study to test the safety of a new drug called EBC-129 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will first test EBC-129 by itself to find a safe dose, then test it combined with an existing immunot…

This is the first study in humans testing a new cancer drug called AZD9592. Researchers want to find safe doses and see if it helps control advanced cancers like lung, head/neck, and colorectal tumors. The study will test AZD9592 alone and combined with other cancer treatments in…